Health system costs of metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 65, Issue 3, 2001, Pages 233-240

  Wai, Elaine S ^a   Trevisan, Caroline H ^a   Malfair Taylor, Suzanne C ^a   Mates, Donna ^a   Jackson, Jeremy S ^a   Olivotto, Ivo A ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Breast cancer; Canadian health system; Economic costs; Palliative care

Indexed keywords

ARTICLE; BREAST CANCER; CANCER MORTALITY; CANCER RECURRENCE; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; UNITED STATES;

ADULT; AGE FACTORS; AGED; BREAST NEOPLASMS; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MIDDLE AGED; MORTALITY; NEOPLASM METASTASIS;

EID: 0035058848     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010686118469     Document Type: Article

References (12)

1. Compliance with practice guidelines for nodenegative breast cancer
2. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination
3. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer
4. Improving the quality of life during chemotherapy for advanced breast cancer
5. Stage, age comorbidity, and direct costs of colon, prostate, and breast cancer care
6. Estimating the treatment costs of breast and lung cancer
7. Diagnostic and therapeutic approaches for nonmetastatic breast cancer in Canada, and their associated costs
8. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America
9. High dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America, Letter to the Editor
10. Docetaxel and paclitaxel in breast cancer therapy: Present status and future prospects
11. Addition of Herceptin to first line chemotherapy for HER2 over-expressing metastatic breast cancer markedly increases anticancer activity: A randomized multinational controlled phase III trial